Beam Therapeutics INC Form 4 insider transactions

CEO John Evans sold shares to cover tax obligations and saw options vest upon achievement of development milestones.

Giuseppe Ciaramella, President of Beam Therapeutics, sold shares to cover tax obligations while also seeing options vest due to the achievement of development milestones.

Chief Financial Officer Terry-Ann Burrell reports acquisition of Beam Therapeutics common stock and restricted stock units.

Amy Simon, Chief Medical Officer of Beam Therapeutics Inc., reports the acquisition of 27,500 shares of common stock and additional shares through the employee stock purchase plan.

Giuseppe Ciaramella, President of Beam Therapeutics, reports the acquisition of 35,000 restricted stock units (RSUs) on March 31, 2024.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, acquired 27,500 shares of common stock through restricted stock units on March 31, 2024.

CEO John M. Evans reports selling 60,000 shares of Beam Therapeutics and acquiring 77,500 restricted stock units.